Marker: Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

 Marker Therapeutics reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy

Patient with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy tolerated initial dose level well and achieved complete response after MT-601 treatment

https://www.globenewswire.com/news-release/2023/09/11/2740646/0/en/Marker-Therapeutics-Announces-Complete-Response-in-First-Lymphoma-Patient-Treated-with-MT-601-after-CAR-T-Relapse.html